Togaviridae infectious disease

This Phase 3 trial will test whether giving the dengue and chikungunya vaccines at the same time is as safe and effective as giving them separately. The study involves 900 healthy adults aged 18 to 59 who have never been exposed to either virus. Researchers will measure immune re…

This early-stage trial tests a new vaccine called PepGNP-ChikV, made from tiny synthetic particles, to see if it is safe and triggers an immune response against chikungunya virus. Forty healthy adults aged 18 to 60 will receive two doses 42 days apart. The study focuses on safety…

This study tests whether a 20-session exercise program can improve muscle strength, reduce fatigue, and help with balance in people who had dengue or chikungunya in the last five years. Fifty-four adults will do supervised aerobic, strength, and breathing exercises twice a week. …